Our clinical and mechanistic data indicated that RUNX3 may be a tumor suppressor involved in the progression of prostate cancer and targeting of RUNX3 pathway constituted a potential treatment modality for human prostate cancer. This evidence concerns the gene RUNX3 and prostate cancer.